Stephane bancel, CEO of Moderna Therapeutics

New York, Jan 25 US-based drugmaker Moderna on Monday said its Covid-19 vaccine retains neutralising activity against emerging variants first identified in the UK and South Africa.Vaccination with the Moderna Covid-19 Vaccine produced neutralising titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and South Africa, respectively, the company said on the basis of a study.However, the company also said it will test an additional booster dose of its Covid-19 vaccine (mRNA-1273) to study the ability to further increase neutralising titers against emerging strains beyond the existing primary vaccination series.Second, the company is advancing an emerging variant booster candidate (mRNA-1273.351) against the B.1.351 variant first identified in South Africa.The company is advancing mRNA-1273.351 into preclinical studies and a Phase 1 study in the US to evaluate the immunological benefit of boosting with strain-specific spike proteins.Moderna expects that its mRNA-based booster vaccine (whether mRNA-1273 or mRNA-1273.351) will be able to further boost neutralising titers in combination with all of the leading vaccine candidates."As we seek to defeat the Covid-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves. We are encouraged by these new data, which reinforce our confidence that the Moderna Covid-19 vaccine should be protective against these newly detected variants," Stephane Bancel, Chief Executive Officer of Moderna, said in a statement."Out of an abundance of caution and leveraging the flexibility of our mRNA platform, we are advancing an emerging variant booster candidate against the variant first identified in the Republic of South Africa into the clinic to determine if it will be more effective to boost titers against this and potentially future variants."( With inputs from IANS )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Stephane BancelFOLLOW

Stephane bancel, Latest News

Washington, June 2 US-based pharmaceutical and biotechnology company Moderna has sought the US Food and Drug Administration (FDA) ... ...

Moderna on Tuesday announced that various studies have shown its COVID-19 vaccine was 100 per cent effective at preventing infection in adolescents aged 12 to 17 and it planned on submitting the findings to global regulators in days. ...

Vaccination with a booster shot among as many people as possible is a good way to protect those most at risk against ever-emerging new coronavirus variants, Moderna CEO Stephane Bancel said on Sunday. ...

At least nine people have become new billionaires since the beginning of Covid pandemic, thanks to the excessive profits pharmaceutical corporations with monopolies on Covid vaccines are making, the People's Vaccine Alliance said on Thursday ahead of ...

Moderna announced on Tuesday (local time) that their coronavirus vaccine was 90 per cent effective six months after a person receives their second dose. ...

Moderna has begun testing its COVID-19 vaccine on children and infants between the ages of six months and 12 years old in a study, as the pharmaceutical company seeks to expand approval for its vaccine to children, the company said on Tuesday. ...

New York, March 16 Biotechnology company Moderna announced that the first participants have been dosed in the Phase ... ...

New York, Jan 25 US-based drugmaker Moderna on Monday said its Covid-19 vaccine retains neutralising activity against emerging ... ...